ARMP
Armata Pharmaceuticals, Inc.
$7.58
+1.47%
$278.3M
No data for this timeframe.
Vol
Market Cap$278.3M
Cap SizeMicro Cap
Inst. Holders20 funds
Inst. Value$9.7M
Inst. Activity2 buys / 1 sells
SEC Reports2
Exchange NYSE·Sector Biological Products, (No Diagnostic Substances)·Inc. WA·CIK 0000921114·Prev Close $7.47
Recent Activity
May 13, 2026
SEC
Armata Pharmaceuticals entered into a $25M secured credit facility with Innoviva at 14% interest to fund AP-SA02 develop
8-K — Impact 6/10
Apr 27, 2026
SEC
Armata Pharmaceuticals appointed Dr. Daniel Gilmer, a biopharmaceutical commercial executive with experience at Pfizer a
8-K — Impact 3/10
Apr 24, 2026
Insider
Gilmer Daniel B. was granted 51,280 shares
Director
Mar 14, 2026
Insider
Birx Deborah surrendered for taxes 4,919 shares
Chief Executive Officer @ $10.54 ($51.8K)
Mar 14, 2026
Insider
Kyme Pierre surrendered for taxes 1,030 shares
Chief Business Officer @ $10.54 ($10.9K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
38,496 shares ($394.2K)
Inst.
BANK OF AMERICA CORP — DOUBLED
11,714 shares ($120.0K)
May 7, 2026
earnings_calendar
ARMP Q1 2026 Earnings Scheduled — 2026-05-07
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$17.50 (Feb 2026)
Current $7.58
Low $15.00
Median $17.50
High $20.00
2 analysts
$15.00
$20.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 5, 2026 | Jones Trading | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.45 ▼ -14.1% | $-0.48 — $-0.41 | 1% YoY | 2 |
| Next Q | $-0.39 ▼ -69.6% | $-0.53 — $-0.25 | 47% YoY | 2 |
| Current FY | $-3.81 ▼ -230.9% | $-4.65 — $-2.96 | 21% YoY | 2 |
| Next FY | $-1.34 ▼ -44.1% | $-1.92 — $-0.76 | 65% YoY | 2 |
Latest Reports
BEARISH
8-K
6/10
Armata Pharmaceuticals entered into a $25M secured credit facility with Innoviva at 14% interest to fund AP-SA02 develop
May 13, 2026
NEUTRAL
8-K
3/10
Armata Pharmaceuticals appointed Dr. Daniel Gilmer, a biopharmaceutical commercial executive with experience at Pfizer a
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3.7M | — |
| EDGEWOOD MANAGEMENT LLC | $1.0M | — |
| SEI INVESTMENTS CO | $759.7K | — |
| VANGUARD FIDUCIARY TRUST CO | $694.9K | — |
| BlackRock, Inc. | $666.1K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 24, 2026 | Gilmer Daniel | A | $0.00 |
| Mar 14, 2026 | Birx Deborah | F | $51.8K |
| Mar 14, 2026 | Kyme Pierre | F | $10.9K |
| Mar 9, 2026 | Peterson Todd | A | $0.00 |
| Mar 9, 2026 | Haimovitz Jules | A | $0.00 |
20 institutional holders with $9.7M total value (954,414 shares) as of 2026-Q1. Top holders: VANGUARD, EDGEWOOD, SEI. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 366,028 | $3.7M | 38.8% | — |
| 2 | EDGEWOOD MANAGEMENT LLC | 100,000 | $1.0M | 10.6% | — |
| 3 | SEI INVESTMENTS CO | 74,192 | $759.7K | 7.9% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 67,864 | $694.9K | 7.2% | — |
| 5 | BlackRock, Inc. | 65,050 | $666.1K | 6.9% | DOUBLED +172.9% |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 64,759 | $663.1K | 6.9% | — |
| 7 | GOLDMAN SACHS GROUP INC | 60,953 | $624.2K | 6.5% | — |
| 8 | STATE STREET CORP | 50,800 | $520.2K | 5.4% | ADD +26.1% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 38,496 | $394.2K | 4.1% | TRIM -43.8% |
| 10 | Hudson Bay Capital Management LP | 17,584 | $180.1K | 1.9% | — |
| 11 | CAPTRUST FINANCIAL ADVISORS | 13,140 | $134.6K | 1.4% | — |
| 12 | BANK OF AMERICA CORP /DE/ | 11,714 | $120.0K | 1.2% | DOUBLED +233.2% |
| 13 | CITIGROUP INC | 5,160 | $52.8K | 0.5% | — |
| 14 | Vanguard Global Advisers, LLC | 3,964 | $40.6K | 0.4% | — |
| 15 | MORGAN STANLEY | 3,367 | $34.5K | 0.4% | ADD +48.4% |
| 16 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 571 | $5.8K | 0.1% | — |
| 17 | BARCLAYS PLC | 154 | $1.6K | 0.0% | — |
| 18 | FMR LLC | 22 | $225.00 | 0.0% | — |
| 19 | HRT FINANCIAL LP | 10,595 | $108.00 | 0.0% | — |
| 20 | WELLS FARGO & COMPANY/MN | 1 | $5.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 68,496 | 38,496 | -43.8% | $394.2K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 3,516 | 11,714 | +233.2% | $120.0K | 2026-Q1 |
| MORGAN STANLEY | ADD | 2,269 | 3,367 | +48.4% | $34.5K | 2026-Q1 |
| BlackRock, Inc. | DOUBLED | 26,666 | 72,764 | +172.9% | $457.0K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 41,296 | 68,496 | +65.9% | $430.2K | 2025-Q4 |
| STATE STREET CORP | ADD | 40,300 | 50,800 | +26.1% | $319.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 7 | 3,516 | +50128.6% | $22.1K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 2 | 2,269 | +113350.0% | $14.3K | 2025-Q4 |
| UBS Group AG | DOUBLED | 1 | 44 | +4300.0% | $131.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 103 | 7 | -93.2% | $21.00 | 2025-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 109 | 2 | -98.2% | $6.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 1,746 | 1 | -99.9% | $2.00 | 2025-Q2 |
| UBS Group AG | TRIM | 6,313 | 1,746 | -72.3% | $2.5K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 634,032 | 93 | -100.0% | $136.00 | 2025-Q1 |
| GROUP ONE TRADING LLC | TRIM | 20,314 | 11,614 | -42.8% | $21.5K | 2024-Q4 |
| UBS Group AG | DOUBLED | 2,357 | 6,313 | +167.8% | $11.7K | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 16,481 | 7,800 | -52.7% | $18.5K | 2024-Q3 |
| MORGAN STANLEY | DOUBLED | 2 | 109 | +5350.0% | $258.00 | 2024-Q3 |
10 unique insiders with 12 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 24, 2026 | Gilmer Daniel B. | Director | AWARD | 51,280 | — | — |
| Mar 14, 2026 | Birx Deborah | Chief Executive Officer | TAX W/H | 4,919 | $10.54 | $51.8K |
| Mar 14, 2026 | Kyme Pierre | Chief Business Officer | TAX W/H | 1,030 | $10.54 | $10.9K |
| Mar 9, 2026 | Peterson Todd C. | Director | AWARD | 25,640 | — | — |
| Mar 9, 2026 | Haimovitz Jules | Director | AWARD | 25,640 | — | — |
| Mar 9, 2026 | Schlesinger Sarah J. | Director | AWARD | 25,640 | — | — |
| Mar 9, 2026 | Birx Deborah | Chief Executive Officer | AWARD | 421,226 | — | — |
| Mar 9, 2026 | PATTI JOSEPH M | Director | AWARD | 25,640 | — | — |
| Mar 9, 2026 | House David Duane | SVP, Finance, and PFO | AWARD | 109,885 | — | — |
| Mar 9, 2026 | Kramer Robin | Director | AWARD | 25,640 | — | — |
| Mar 9, 2026 | Kyme Pierre | Chief Business Officer | AWARD | 183,142 | — | — |
| Mar 9, 2026 | Odysseas Kostas D | Director | AWARD | 25,640 | — | — |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 4.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2026): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$17.50 mean target (Feb 2026)
$15.00 Low
$20.00 High
| Metric | Value |
|---|---|
| Current Price | $7.58 |
| Target Low | $15.00 |
| Target Mean | $17.50 |
| Target Median | $17.50 |
| Target High | $20.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.45 | $-0.48 | $-0.41 | 1.1% | -14.1% | 0↑ 1↓ | $0.0B | -80.6% | 2 |
| Next Q 2026-09-30 |
$-0.39 | $-0.53 | $-0.25 | 47.3% | -69.6% | — | $0.0B | -61.2% | 2 |
| Current FY 2026-12-31 |
$-3.81 | $-4.65 | $-2.96 | 20.7% | -230.9% | 0↑ 1↓ | $0.0B | -55.1% | 2 |
| Next FY 2027-12-31 |
$-1.34 | $-1.92 | $-0.76 | 64.8% | -44.1% | 1↑ 0↓ | $0.0B | 25.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.445 | |
| 7d ago | $-0.480 | +0.035 |
| 30d ago | $-0.390 | -0.055 |
| 60d ago | $0.000 | -0.445 |
| 90d ago | $0.000 | -0.445 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | Jones Trading | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
ARMP Q1 2026 Earnings Scheduled — 2026-05-07
Apr 1, 2026
Clinical Trial
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Phase Phase 2 — COMPLETED
Mar 19, 2026
earnings_calendar
ARMP Q4 2025 Earnings After Market Close — 2026-03-19